[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100614945":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":45,"responsibleParty":63,"collaborators":26,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":26,"eligibilityCriteria":72,"healthyVolunteers":68,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":26,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},{"fullName":5,"class":6},"Northwestern University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Misoprostol (treatment aem)","EXPERIMENTAL","Patients will received 800 mcg of misoprostol per rectum prior to procedure.",[13],"Drug: Misoprostol Tabets",{"label":15,"type":16,"description":17,"interventionNames":18},"Zeebo (Placebo arm)","PLACEBO_COMPARATOR","Patient will receive 4 tablets of placebo (ZEEBO) per rectum prior to procedure.",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Misoprostol Tabets","800 mcg of misoprostol will be administered per rectum to intervention group prior to their scheduled hysteroscopic myomectomy.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","4 tablets of Zeebo (Microcsrystalline cellulose) placebo tablets will be placed per rectum to prior to undergoing a hysteroscopic myomectomy, for patients assigned to the placebo arm.",[15],[32],{"name":33,"affiliation":34,"role":35},"Magy Milad, MD","Northwestern University Feinberg School of Medicine, Northwestern Department of Obstetrics and Gynecology, Division of Minimally Invasive Gyn Surgery","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Hannah Pope, MD","CONTACT","3126946773","hannah.pope@nm.org",{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},"Juan Avitia, MPH","juan.avitia1@nm.org",[46],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Northwestern","RECRUITING","Chicago","Illinois","60611","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-87.65005,41.85003,{"lat":58,"lon":57},[61,62],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":43,"role":39,"phone":26,"phoneExt":26,"email":44},{"type":35,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"Magdy Milad, MD","Albert B Gerbie Professor","100614945","phase-4-effect-of-misoprostol-on-fluid-deficit-volume-in-hysteroscopic-myomectomy-100614945",false,"NCT07286188","Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy","Effect of Misoprostol on Fluid Deficit Volume in Hysteroscopic Myomectomy: A Double-Blinded Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients presenting for hysteroscopic myomectomy for uterine fibroids on pelvic imaging (pelvic ultrasound or MRI) within in last 12 months\n* Age ≥ 18 years and ≤ 50 years.\n* Fibroids between 1-3cm in size\n* Myomectomy using myosure or resectoscope devices\n* Willing to have rectal misoprostol or placebo at time of procedure\n* Ability to understand and the willingness to sign a written informed consent.\n* Admissible medical\u002Fsurgical history.\n* Can be previously treated with Depo-Lupron, Depo-Provera, or Oral Contraceptive pills\n* Can have had prior Cesarean delivery\n\nExclusion Criteria:\n\n* Pregnancy. All patients will be required to have a negative urine pregnancy test prior to surgery.\n* Post-menopausal women.\n* Patients with a history of gynecologic malignancy.\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to misoprostol.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Known active inflammatory bowel disease involving the rectum or other significant anorectal conditions that may interfere with safe rectal administration of study medication.","FEMALE","18 Years","50 Years",{"count":77,"type":78},40,"ESTIMATED","INTERVENTIONAL",[81],"PHASE4","The goal of this double blinded randomized control trial is to evaluate the impact of misoprostol on fluid deficit during hysteroscopic myomectomies. The main questions it aims to answer are:\n\nIs there is difference in fluid deficit in patients who receive misoprostol vs placebo pre operatively for hysteroscopic myomectomies?\n\nParticipants will be randomized to received 800 mcg of either rectal misoprostol prior to their hysteroscopic myomectomy or 4 tablets of placebo (ZEEBO) prior to their hysteroscopic myomectomy.",[84,85,86],"Fibroids, Uterine","Fluid Deficit","Hysteroscopy \u002F Methods",[88,89,90,91,92],"fibroids","hysteroscopy","myomectomy","fluid deficit","misoprostol","2026-05-28",{"date":95,"type":96},"2026-06-01","ACTUAL",{"date":98,"type":96},"2025-12-16",{"date":100,"type":78},"2026-12",{"name":5,"class":6},1]